A Medina-Herrera, I Vazquez, I Cuenca, J M Rosa-Rosa, B Ariceta, C Jimenez, M Fernandez-Mercado, M J Larrayoz, N C Gutierrez, M Fernandez-Guijarro, V Gonzalez-Calle, P Rodriguez-Otero, A Oriol, L Rosiñol, A Alegre, F Escalante, J De La Rubia, A I Teruel, F De Arriba, M T Hernandez, J Lopez-Jimenez, E M Ocio, N Puig, B Paiva, J J Lahuerta, J Bladé, J F San Miguel, M V Mateos, J Martinez-Lopez, M J Calasanz, R Garcia-Sanz
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance...
April 29, 2024: Blood Cancer Journal